SNPMiner Trials (Home Page)
Report for SNP rs1061325
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 The Role of Genetic Variation in CLTCL1 and Other Related Genes in Relation to Whole-body Glucose Control: A Pilot Study
Maintaining stable blood glucose concentrations after eating has important implications for health. Individuals who are better able to maintain stable blood glucose concentrations after consuming carbohydrate have a lower risk of mortality from cardiovascular disease. Muscle is the primary tissue for glucose disposal following a meal, and responsiveness of this tissue to insulin is dictated by GLUT4 translocation to the muscle cell membrane. Clathrin heavy chain isoform 22 (CHC22) is a protein that plays a key role in intracellular GLUT4 action, and it may play an important role in whole-body glucose control. Genetic variation in the gene which codes for CHC22 may be able to explain differences in glucose control at the whole-body level.
NCT03998111 Glucose Control Diagnostic Test: Oral glucose tolerance test
Cell-based studies suggest that genetic variation in the CLTCL1 gene (which encodes for CHC22) at SNP rs1061325, influences GLUT4 retention.
Primary Outcomes
Description: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by CHC22 genotype.
Measure: Plasma glucose incremental area under the curve (CHC22 genotype) Time: 2 hoursDescription: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the peak glucose concentration will be measured, this will be grouped by CHC22 genotype.
Measure: Peak plasma glucose (CHC22 genotype) Time: 2 hoursSecondary Outcomes
Description: Plasma glucose will be measured at baseline and will be grouped by CHC22 genotype.
Measure: Fasting plasma glucose concentrations (CHC22 genotype) Time: 2 hoursDescription: Plasma glucose samples will be obtained throughout the 2-hour postprandial period and the incremental area under the curve will be calculated, this will be grouped by genotyping other genes related to glucose control or sweet taste sensitivity.
Measure: Plasma glucose incremental area under the curve (other genotypes) Time: 2 hoursDescription: Plasma glucose will be measured at baseline and will be grouped by genotypes related to glucose control and sweet taste sensitivity.
Measure: Fasting plasma glucose concentrations (other genotypes) Time: 2 hoursDescription: Matsuda insulin sensitivity index will be calculated using blood samples collected in the 2-hour postprandial period.
Measure: Matsuda insulin sensitivity index Time: 2 hoursDescription: Homeostasis model of insulin resistance will be calculated using blood samples collected in the 2-hour postprandial period.
Measure: Homeostasis model of insulin resistance Time: 2 hours